Prenetics Global Limited (NASDAQ:PRE) Sees Significant Drop in Short Interest

Prenetics Global Limited (NASDAQ:PRE) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 39,900 shares, a decrease of 36.5% from the August 31st total of 62,800 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average trading volume of 68,900 shares, the days-to-cover ratio is presently 0.6 days. Based on an average trading volume of 68,900 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.5% of the company’s stock are sold short.

Institutional Investors Weigh In On Prenetics Global

An institutional investor recently bought a new position in Prenetics Global stock. Stevens Capital Partners bought a new position in Prenetics Global Limited (NASDAQ:PRE) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 17,382 shares of the company’s stock, valued at approximately $137,000. Stevens Capital Partners owned 0.13% of Prenetics Global at the end of the most recent reporting period. Hedge funds and other institutional investors own 25.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PRE. Wall Street Zen upgraded Prenetics Global to a “hold” rating in a report on Saturday, July 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a report on Saturday, September 27th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Prenetics Global has a consensus rating of “Hold” and an average price target of $9.00.

Prenetics Global Stock Performance

NASDAQ:PRE opened at $14.27 on Friday. The stock’s 50 day moving average price is $9.34 and its 200 day moving average price is $7.53. Prenetics Global has a 52 week low of $3.09 and a 52 week high of $15.35. The company has a market capitalization of $185.22 million, a P/E ratio of -3.58 and a beta of 0.34.

Prenetics Global (NASDAQ:PRE) last released its quarterly earnings data on Friday, September 12th. The company reported ($0.82) EPS for the quarter. Prenetics Global had a negative return on equity of 31.05% and a negative net margin of 87.92%.The firm had revenue of $17.68 million during the quarter. Prenetics Global has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Prenetics Global will post -3.3 earnings per share for the current fiscal year.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.